Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad

Thomas Lee, Lahiru Russell, Minfeng Deng, Peter Raymond Gibson

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

Background: The risks are unknown for developing chronic gastrointestinal illness when personnel are relocated short term to other countries and when taking antibiotic prophylaxis in areas where malaria is endemic. Aim: To examine the associations of deployment to developed or developing countries and exposure to doxycycline with the new onset of acute gastroenteritis, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Methods: A cross-sectional web-based survey of all current and past members of the Australian Federal Police Association was undertaken. Independent predictors of gastrointestinal illness were examined by logistic regression analysis relative to those not deployed without exposure to doxycycline. Results: Of 1300 respondents (response rate 34 ), 133 were excluded due to preexisting chronic gastrointestinal illness. Five hundred and ninety had episodes of overseas deployment for a median duration of 6.5 (range 0.1?149) months. Eighteen (3 ) of those not deployed took doxycycline compared with 171 (30 ) of those deployed. The risk of acute gastroenteritis was associated with deployment itself without clear association with doxycycline. Doxycycline exposure was associated with increased onset of IBS in those deployed to developing (odds ratio [OR], 6.99; 95 confidence interval [CI], 3.19?15.31) and developed country (OR, 6.93; 95 CI, 1.40?34.39). New onset of IBD (1.5 ) was associated with deployment to developed countries and with doxycycline exposure (OR, 8.75; 95 CI, 1.67?45.86)). Conclusions: The use of doxycycline is a risk factor for developing IBS and possibly IBD when deployed to developing and developed countries respectively. Doxycycline as a risk factor for chronic gastrointestinal illness warrants a prospective large-scale study.
Original languageEnglish
Pages (from-to)919 - 926
Number of pages8
JournalInternal Medicine Journal
Volume43
Issue number8
DOIs
Publication statusPublished - 2013

Cite this

@article{7965fbe71f964faa8e61893d02c7aff6,
title = "Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad",
abstract = "Background: The risks are unknown for developing chronic gastrointestinal illness when personnel are relocated short term to other countries and when taking antibiotic prophylaxis in areas where malaria is endemic. Aim: To examine the associations of deployment to developed or developing countries and exposure to doxycycline with the new onset of acute gastroenteritis, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Methods: A cross-sectional web-based survey of all current and past members of the Australian Federal Police Association was undertaken. Independent predictors of gastrointestinal illness were examined by logistic regression analysis relative to those not deployed without exposure to doxycycline. Results: Of 1300 respondents (response rate 34 ), 133 were excluded due to preexisting chronic gastrointestinal illness. Five hundred and ninety had episodes of overseas deployment for a median duration of 6.5 (range 0.1?149) months. Eighteen (3 ) of those not deployed took doxycycline compared with 171 (30 ) of those deployed. The risk of acute gastroenteritis was associated with deployment itself without clear association with doxycycline. Doxycycline exposure was associated with increased onset of IBS in those deployed to developing (odds ratio [OR], 6.99; 95 confidence interval [CI], 3.19?15.31) and developed country (OR, 6.93; 95 CI, 1.40?34.39). New onset of IBD (1.5 ) was associated with deployment to developed countries and with doxycycline exposure (OR, 8.75; 95 CI, 1.67?45.86)). Conclusions: The use of doxycycline is a risk factor for developing IBS and possibly IBD when deployed to developing and developed countries respectively. Doxycycline as a risk factor for chronic gastrointestinal illness warrants a prospective large-scale study.",
author = "Thomas Lee and Lahiru Russell and Minfeng Deng and Gibson, {Peter Raymond}",
year = "2013",
doi = "10.1111/imj.12179",
language = "English",
volume = "43",
pages = "919 -- 926",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "8",

}

Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad. / Lee, Thomas; Russell, Lahiru; Deng, Minfeng; Gibson, Peter Raymond.

In: Internal Medicine Journal, Vol. 43, No. 8, 2013, p. 919 - 926.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad

AU - Lee, Thomas

AU - Russell, Lahiru

AU - Deng, Minfeng

AU - Gibson, Peter Raymond

PY - 2013

Y1 - 2013

N2 - Background: The risks are unknown for developing chronic gastrointestinal illness when personnel are relocated short term to other countries and when taking antibiotic prophylaxis in areas where malaria is endemic. Aim: To examine the associations of deployment to developed or developing countries and exposure to doxycycline with the new onset of acute gastroenteritis, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Methods: A cross-sectional web-based survey of all current and past members of the Australian Federal Police Association was undertaken. Independent predictors of gastrointestinal illness were examined by logistic regression analysis relative to those not deployed without exposure to doxycycline. Results: Of 1300 respondents (response rate 34 ), 133 were excluded due to preexisting chronic gastrointestinal illness. Five hundred and ninety had episodes of overseas deployment for a median duration of 6.5 (range 0.1?149) months. Eighteen (3 ) of those not deployed took doxycycline compared with 171 (30 ) of those deployed. The risk of acute gastroenteritis was associated with deployment itself without clear association with doxycycline. Doxycycline exposure was associated with increased onset of IBS in those deployed to developing (odds ratio [OR], 6.99; 95 confidence interval [CI], 3.19?15.31) and developed country (OR, 6.93; 95 CI, 1.40?34.39). New onset of IBD (1.5 ) was associated with deployment to developed countries and with doxycycline exposure (OR, 8.75; 95 CI, 1.67?45.86)). Conclusions: The use of doxycycline is a risk factor for developing IBS and possibly IBD when deployed to developing and developed countries respectively. Doxycycline as a risk factor for chronic gastrointestinal illness warrants a prospective large-scale study.

AB - Background: The risks are unknown for developing chronic gastrointestinal illness when personnel are relocated short term to other countries and when taking antibiotic prophylaxis in areas where malaria is endemic. Aim: To examine the associations of deployment to developed or developing countries and exposure to doxycycline with the new onset of acute gastroenteritis, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Methods: A cross-sectional web-based survey of all current and past members of the Australian Federal Police Association was undertaken. Independent predictors of gastrointestinal illness were examined by logistic regression analysis relative to those not deployed without exposure to doxycycline. Results: Of 1300 respondents (response rate 34 ), 133 were excluded due to preexisting chronic gastrointestinal illness. Five hundred and ninety had episodes of overseas deployment for a median duration of 6.5 (range 0.1?149) months. Eighteen (3 ) of those not deployed took doxycycline compared with 171 (30 ) of those deployed. The risk of acute gastroenteritis was associated with deployment itself without clear association with doxycycline. Doxycycline exposure was associated with increased onset of IBS in those deployed to developing (odds ratio [OR], 6.99; 95 confidence interval [CI], 3.19?15.31) and developed country (OR, 6.93; 95 CI, 1.40?34.39). New onset of IBD (1.5 ) was associated with deployment to developed countries and with doxycycline exposure (OR, 8.75; 95 CI, 1.67?45.86)). Conclusions: The use of doxycycline is a risk factor for developing IBS and possibly IBD when deployed to developing and developed countries respectively. Doxycycline as a risk factor for chronic gastrointestinal illness warrants a prospective large-scale study.

UR - http://onlinelibrary.wiley.com/doi/10.1111/imj.12179/pdf

U2 - 10.1111/imj.12179

DO - 10.1111/imj.12179

M3 - Article

VL - 43

SP - 919

EP - 926

JO - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

IS - 8

ER -